Myofibrillar myopathy (MFM) is a group of inherited disorders characterized by progressive muscle weakness and atrophy due to dysregulation of the myofibril structure in muscle fibers. The disorder is most often associated with changes in the structure of proteins that make up sarcomeres, leading to dysfunction and extensive muscle damage. The main clinical manifestations include progressive muscle weakness, often beginning in childhood or adolescence, and possible additional symptoms such as cardiomyopathy and heart rhythm disturbances. Myofibrillar myopathy is a fairly diverse pathological condition with different clinical forms determined by mutations in specific genes.
History of the disease and interesting historical facts
The first description of myofibrillar myopathy was made in the early 19th century, when scientists began to identify various forms of muscle diseases. However, it was only in the 1990s with the development of molecular genetics that significant progress was made in understanding the pathogenesis of MFM. One of the important historical stages was the discovery of mutations in the genes encoding the structural proteins of myofibrils, which made it possible to establish the genetic basis of this disease. Interestingly, myofibrillar myopathy was practically unstudied until the 2000s, when active genetic testing and identification of new mutations began.
Epidemiology
The prevalence of myofibrillar myopathy is estimated to be between 1 and 9 cases per 100,000 population. This rare form of myopathy is more common in males than females, although the exact mechanisms for this disparity are not yet understood. Studies suggest that certain populations may be more susceptible to the disease due to a high carrier frequency of mutations in associated genes. Epidemiological studies have indicated the presence of forms of myofibrillar myopathy with different opacity depending on the geographic region, which may be associated with certain genetic isolates.
Genetic predisposition to this disease
Myofibrillar myopathy is associated with several mutations in different genes, the most commonly involved are:
- MYOT (myosin, heavy ocular muscle type),
- DES (destin),
- TPM2 (tropomyosin 2),
- ZASP (Z-band alternatively spliced PDZ-motif protein).
These mutations are often inherited in an autosomal dominant or autosomal recessive manner. Massive genome sequencing has identified many new mutations, confirming the high genetic heterogeneity of the disease. There are also rare forms of myofibrillar myopathy caused by mutations in genes involved in mitochondrial function and energy production.
Risk factors for the development of this disease
Although myofibrillar myopathy is most often a hereditary disease, there are certain risk factors that can affect the severity of symptoms and the progression of the disease:
- Heredity - having close relatives with similar diseases increases the risk,
- Certain gene mutations associated with specific forms of MFM
- Older age - symptoms may be more severe in people over 50 years of age,
- The presence of concomitant diseases such as diabetes or coronary heart disease.
Chemical factors, such as certain medications and toxins, may also worsen symptoms, but their effects are not fully understood.
Diagnosis of this disease
Diagnosis of myofibrillar myopathy involves a comprehensive approach and includes several key stages:
- The main symptoms are progressive muscle weakness, muscle atrophy, muscle pain, and possible cardiac symptoms such as arrhythmia.
- Lab tests: Complete blood count, creatine kinase level, which may indicate muscle damage.
- Radiological tests such as magnetic resonance imaging (MRI) can help visualize the affected muscles.
- Muscle biopsy: allows for histological examination and identification of changes in the structure of myofibrils.
- Genetic testing: can identify specific mutations and differentiate MFM from other myopathies.
Differential diagnosis includes exclusion of other myopathies such as Duchenne muscular dystrophy and myasthenia gravis, as well as neurological diseases.
Treatment
Treatment of myofibrillar myopathy is supportive and symptomatic, as it is currently impossible to completely cure the disease. The main approaches include:
- Pharmacological treatment: May include corticosteroids to slow disease progression and improve muscle health.
- Physical therapy: The use of exercise to maintain muscle strength and function.
- Surgical treatment: In some cases, surgery may be required to correct complications such as scoliosis.
- Lifestyle tips: Include a protein-rich diet and regular exercise under the supervision of a specialist.
A combined approach to treatment allows us to maximally improve the quality of life of patients.
List of medications used to treat this disease
The following groups of drugs can be used as part of the complex treatment of myofibrillar myopathy:
- Corticosteroids (eg, prednisolone),
- Myostimulators (means for improving the conductivity of nerve impulses),
- Rehabilitation supplements and vitamins (eg, vitamin D to improve bone health).
Each drug is prescribed to the patient individually, taking into account their condition and the progression of the disease.
Disease monitoring
Monitoring the condition of patients with myofibrillar myopathy requires regular examinations:
- Monitoring the functionality of muscles and the cardiovascular system, which allows for timely detection of complications,
- The prognosis depends on early diagnosis and immediate initiation of treatment; if left untreated, the disease can significantly worsen the quality of life.
- Complications may include cardiac arrhythmias, heart failure, and progressive muscle fiber death.
The introduction of comprehensive monitoring allows us to avoid serious consequences and improve the prognosis.
Age-related features of the disease
Myofibrillar myopathy can manifest itself in different age groups, which affects its progression:
- In children and adolescents, the disease often begins with a rapid deterioration in muscle function and can progress rapidly,
- In adult patients, symptoms may develop more gradually, often taking the form of hypotonic and atrophic changes,
- In older people, myofibrillar myopathy may be worsened by other age-related diseases such as osteoporosis or hypertension, making treatment more difficult.
Consultation with doctors of different specialties is necessary for adequate monitoring and treatment that takes into account age-related characteristics.
Questions and Answers
- What is myofibrillar myopathy? This is a group of hereditary diseases characterized by progressive muscle weakness and disruption of the structure of myofibrils.
- How is myofibrillar myopathy diagnosed? Diagnosis includes evaluation of symptoms, laboratory tests, muscle biopsy, and genetic testing.
- What treatment is available for myofibrillar myopathy? Treatment includes drug therapy, physical therapy, surgery, and lifestyle changes.
- Who is more susceptible to myofibrillar myopathy? The disease is more common in men and often has a hereditary predisposition.
- What is the prognosis for patients with myofibrillar myopathy? The prognosis depends on timely diagnosis and treatment; without treatment, serious complications are possible.
In conclusion, myofibrillar myopathy remains a challenge for patients and physicians. Early diagnosis and adherence to a comprehensive approach to treatment and monitoring can significantly improve quality of life and slow disease progression.
